Asia-Pacific Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a pressing need for more patient-centric, data-driven, value-based, and precise solutions in oncology. Additionally, Asian cancer patients’ healthcare needs can differ…

APAC COVID-19 has pushed diagnostics to the forefront of healthcare conversations across the world. Here, three leading lights from the Asia-Pacific medtech industry weigh in on what the new diagnostics paradigm might look like as the pandemic recedes.   Sanjay Prabhakaran, president Asia Pacific, Hologic “One positive outcome of this pandemic…

Singapore Regulatory harmonisation for medical devices between countries in Asia-Pacific has long been a challenging issue, predominantly due to the extreme variation in cultures, economic development, governmental models, and healthcare systems in the region.   Greater harmonisation would allow solutions introduced in APAC’s most developed markets to filter down to its…

Singapore Singapore – despite its modest USD 1.22 billion domestic market – has long been one of Asia’s leading biopharmaceutical hubs and a magnet for top talent. Multitudes of biopharma and medtech multinationals, as well as domestic start-ups, have based regional functions in the clean, English speaking, and well-developed city-state with…

Singapore As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other markets. This situation keeps the Health Sciences Authority (HSA) – the country’s regulatory body – extremely busy. While challenges, including…

Asia-Pacific At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems in APAC means that a region accounting for 60 percent of the world’s population only represents a quarter of global…

Singapore The ongoing COVID-19 pandemic is a double-edged sword for Singapore. While its economy has been hit by the global crisis, the island city-state is seeing an uptick in pharmaceutical manufacturing exports to countries looking to stock up on active pharmaceutical ingredients (APIs).   Singapore’s pharmaceutical output has jumped 86 percent…

Singapore A roundup of some of the most significant healthcare and life science stories from across Singapore and the Asia-Pacific region, including the ongoing hunt for a COVID-19 vaccine and a significant acquisition for Korean Celltrion.   Coronavirus vaccine: Singapore scientists discover 5 antibodies that can combat COVID-19 https://www.businesstoday.in/sectors/pharma/coronavirus-vaccine-singapore-scientists-discover-5-antibodies-that-can-combat-covid/story/407214.html A team…

Digital Health Rhenu Bhuller, a founding member of Frost & Sullivan’s Asia Pacific operations and expert in analysing the impact of cutting-edge tech, looks at pharma’s evolution and adoption of digital health.   The evolution of disease management and the convergence of drugs, devices and digital health in the management of various…

Diversity Ai Hua Ong, Company Group Chairman, Asia Pacific, The Janssen Pharmaceutical Companies of Johnson & Johnson.   There is a clear correlation between an inclusive culture and innovation Creating a diverse workforce and an inclusive culture is key to an organisation’s success in today’s and tomorrow’s world. Organisations large and…

Singapore Singapore’s location at the heart of the APAC region, expertise in logistics and cold chain management, and smart investment in infrastructure has helped make the Lion City an indisputable global heavyweight in pharma logistics. “From a logistics standpoint, Singapore serves as a pivotal gateway to the broader region—namely because of…

Singapore The Asia-Pacific region is a vast geographic area, home to almost half of the world’s population and numerous emerging and developed markets with great investment potential for healthcare and life sciences companies. However, the degree of diversity within Asia-Pacific creates formidable challenges for MNCs operating in the region. “APAC is…